【摘 要】目的：观察恩替卡韦对干扰素失败的慢性乙型肝炎的治疗作用和安全性。方法：80例应用干扰素治疗无应答的慢性乙型肝炎患者，分为两组，治疗组38例予恩替卡韦0.5mg/d, 对照组42例予拉米夫定100mg/d,，持续治疗52周，定期检测肝功能、两对半及HBV- DNA水平变化情况。结果：治疗组在4周、12周、36周、52周时的转氨酶复常率分别为60%、79%、84%、95%。对照组分别为26%、60%、67%、93%。治疗组在.4周、12周、36周、52周HBV- DNA水平清除率分别为37% 、84%、90%、92%。对照组为分别为26%、60%、86%、88%。治疗组在52周时HBeAg阴转率为36%，对照组21%。 治疗过程中均无不良反应发生。结论：恩替卡韦治疗慢性乙型肝炎有良好的疗效,且安全性好,无耐药发生。

    【关键词】 恩替卡韦；慢性乙型肝炎

    【中图分类号】R 512.6+2 【文献标识码】A 【文章编号】1004- 7484(2012)04- 0305- 01

    【Abstract】Objective：To study the therapeutic action and reliability of Entecavir on treatment failure patients with chronic hepatitis B(CHB) by interferon. Methods：80 treatment failure patients with chronic hepatitis B (CHB) by interferon were randomly divided into 2 groups, treatment group and control group. 38 patients in treatment group were administered to Entecavir (0.5mg/d) for 52 weeks. However, 42 patients in control group were administered to Lamivudine (100mg/d) for the same course. The levels of alanine transarninase (ALT)、 HBV serologic markers and HBV DNA copies were detected on different points. Results：The ALT recovery rates of treatment group were 60%、79%、84%、95% on 4 weeks、12 weeks、36 weeks、and 52 weeks after treatment ,and differently in control group (26%、60%、67%、93%). The HBV DNA clearance rates of treatment group were 37% 、84%、90%、92% on 4 weeks、12 weeks、36 weeks、and 52 weeks after treatment ,and differently in control group (26%、60%、86%、88%). The HBeAg transition rate of treatment group was 36% on 52 weeks after treatment, and differently in control group (21%). In addition, there was no adverse reaction during the treatment course. Conclusions：Entecavir is effective safety to treat CHB, no resistance. ......